ABCC10 rs2125739 polymorphism and nevirapine-induced hepatotoxicity: Lack of association in a population from Mozambique

Pharmacogenetics and Genomics

Volumn 23, Issue 1, 2013, Pages 38-39

  Ciccacci, Cinzia ^a   Di Fusco, Davide ^a   Marazzi, Maria C ^b   Liotta, Giuseppe ^a   Palombi, Leonardo ^a   Novelli, Giuseppe ^c,d   Borgiani, Paola ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b LUMSA UNIVERSITY   (Italy)

^c Responsable for National Scientific Habilitation   (Italy)

^d FATEBENEFRATELLI HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABCC10 PROTEIN; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; DNA FRAGMENT; MEMBRANE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; NEVIRAPINE; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; DRUG BLOOD LEVEL; ENVIRONMENTAL FACTOR; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HUMAN; LETTER; LIVER TOXICITY; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

EID: 84871922495     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e328359e951     Document Type: Letter

References (6)

1. Liptrott NJ, Pushpakom S, Wyen C, Fätkenheuer G, Hoffmann C, Mauss S,et al. German Competence Network for HIV/AIDS. Association of ABCC10polymorphisms with nevirapine plasma concentrations in the GermanCompetence Network for HIV/AIDS. Pharmacogenet Genomics 2012;22:10-19.
2. Ciccacci C, Borgiani P, Ceffa S, Sirianni E, Marazzi MC, Altan AM, et al.Nevirapine-induced hepatotoxicity and pharmacogenetics: a retrospectivestudy in a population from Mozambique. Pharmacogenomics 2010; 11:23-31.
3. Excoffier LG, Laval, Schneider S. Arlequin ver. 3.0: an integrated softwarepackage for population genetics data analysis. Evol Bioinform Online2005; 1:47-50.
4. Pushpakom SP, Liptrott NJ, Rodr?́guez-Nó voa S, Labarga P, Soriano V,Albalater M, et al. Genetic variants of ABCC10, a novel tenofovir transporter,are associated with kidney tubular dysfunction. J Infect Dis 2011; 204:145-153.
5. Rotger M, Colombo S, Furrer H, Bleiber G, Buclin T, Lee BL, et al. Swiss HIVCohort Study. Influence of CYP2B6 polymorphism on plasma and intracellularconcentrations and toxicity of efavirenz and nevirapine in HIV-infectedpatients. Pharmacogenet Genomics 2005; 15:1-5. (Pubitemid 43205520)
6. Haas DW, Bartlett JA, Andersen JW, Sanne I, Wilkinson GR, Hinkle J, et al.Adult AIDS Clinical Trials Group. Pharmacogenetics of nevirapine- associatedhepatotoxicity: an Adult AIDS Clinical Trials Group collaboration. Clin InfectDis 2006; 43:783-786. (Pubitemid 44330746)